MX2021010311A - Antifúngicos triterpenoides para el tratamiento o prevención de neumonía por pneumocystis spp. - Google Patents

Antifúngicos triterpenoides para el tratamiento o prevención de neumonía por pneumocystis spp.

Info

Publication number
MX2021010311A
MX2021010311A MX2021010311A MX2021010311A MX2021010311A MX 2021010311 A MX2021010311 A MX 2021010311A MX 2021010311 A MX2021010311 A MX 2021010311A MX 2021010311 A MX2021010311 A MX 2021010311A MX 2021010311 A MX2021010311 A MX 2021010311A
Authority
MX
Mexico
Prior art keywords
pneumocystis
spp
prevention
treatment
pneumonia
Prior art date
Application number
MX2021010311A
Other languages
English (en)
Spanish (es)
Inventor
Gonzalez David A Angulo
Stephen Andrew Barat
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of MX2021010311A publication Critical patent/MX2021010311A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MX2021010311A 2019-02-27 2020-02-25 Antifúngicos triterpenoides para el tratamiento o prevención de neumonía por pneumocystis spp. MX2021010311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (1)

Publication Number Publication Date
MX2021010311A true MX2021010311A (es) 2022-01-04

Family

ID=70005768

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021010311A MX2021010311A (es) 2019-02-27 2020-02-25 Antifúngicos triterpenoides para el tratamiento o prevención de neumonía por pneumocystis spp.
MX2025004197A MX2025004197A (es) 2019-02-27 2021-08-26 Antifungicos triterpenoides para el tratamiento o prevencion de neumonia por pneumocystis spp

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025004197A MX2025004197A (es) 2019-02-27 2021-08-26 Antifungicos triterpenoides para el tratamiento o prevencion de neumonia por pneumocystis spp

Country Status (15)

Country Link
US (1) US12594266B2 (cg-RX-API-DMAC7.html)
EP (1) EP3930716B1 (cg-RX-API-DMAC7.html)
JP (1) JP7581219B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210133241A (cg-RX-API-DMAC7.html)
CN (1) CN113631165A (cg-RX-API-DMAC7.html)
AU (1) AU2020228036B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131298A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192344A1 (cg-RX-API-DMAC7.html)
ES (1) ES3055272T3 (cg-RX-API-DMAC7.html)
IL (1) IL285839A (cg-RX-API-DMAC7.html)
MA (1) MA55081A (cg-RX-API-DMAC7.html)
MX (2) MX2021010311A (cg-RX-API-DMAC7.html)
TW (1) TWI910099B (cg-RX-API-DMAC7.html)
WO (1) WO2020176527A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤
PL3661503T3 (pl) 2017-08-04 2023-01-09 Scynexis, Inc. Środki przeciwgrzybicze o zwiększonej aktywności przy kwasowym odczynie ph

Also Published As

Publication number Publication date
KR20210133241A (ko) 2021-11-05
JP7581219B2 (ja) 2024-11-12
US12594266B2 (en) 2026-04-07
EP3930716A1 (en) 2022-01-05
JP2022523212A (ja) 2022-04-21
MA55081A (fr) 2022-01-05
WO2020176527A1 (en) 2020-09-03
IL285839A (en) 2021-10-31
BR112021016876A2 (pt) 2021-11-03
AU2020228036B2 (en) 2025-08-07
AU2020228036A1 (en) 2021-09-23
ES3055272T3 (en) 2026-02-10
MX2025004197A (es) 2025-09-02
US20230149376A1 (en) 2023-05-18
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
EA202192344A1 (ru) 2021-11-15
CN113631165A (zh) 2021-11-09
TWI910099B (zh) 2026-01-01
EP3930716B1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
ZA202204929B (en) Rimegepant for cgrp related disorders
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
GEAP202316326A (en) Pharmaceutical combinations of sos1 inhibitors
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
NZ627181A (en) Method of treating atrial fibrillation
WO2020033838A3 (en) Treatment of egfr-mutant cancer
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
NO20073774L (no) Terapeutiske forbindelser for intranasal administrering av ketorolac
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MX2024002409A (es) Terapias contra el cancer.
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
WO2020217116A3 (en) Long acting inhalation compositions of indacaterol
MX2023001823A (es) Terapia de combinacion.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
CR20220565A (es) Inhibidores de il4i1 y métodos de uso
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2024013068A (es) Métodos de administración de inhibidores de miosina
MX2022012001A (es) Tratamiento preventivo de la migra?a.